These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14996627)

  • 1. Exemestane and aromatase inhibitors in the management of advanced breast cancer.
    Dixon JM
    Expert Opin Pharmacother; 2004 Feb; 5(2):307-16. PubMed ID: 14996627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of exemestane in the management of breast cancer.
    Wong NS; Pritchard KI
    Expert Opin Pharmacother; 2005 Oct; 6(13):2353-63. PubMed ID: 16218894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D; Lamb HM
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-aromatase agents in the treatment and prevention of breast cancer.
    Goss P
    Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and clinical experience with exemestane.
    Lønning PE
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
    Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
    Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the pharmacology of the aromatase inactivator exemestane.
    Brueggemeier RW
    Breast Cancer Res Treat; 2002 Jul; 74(2):177-85. PubMed ID: 12186378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
    Bertelli G; Gangadhara S
    Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors for breast cancer in postmenopausal women.
    Campos SM
    Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aromasin in the hormonal therapy of breast cancer.
    Dank M
    Pathol Oncol Res; 2002; 8(2):87-92. PubMed ID: 12172571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors in the treatment and prevention of breast cancer.
    Goss PE; Strasser K
    J Clin Oncol; 2001 Feb; 19(3):881-94. PubMed ID: 11157042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.